Gerard Sanacora, MD
Enriched profileGeorge D. and Esther S. Gross Professor of Psychiatry; Director, Yale Depression Research Program; Co-Director, Yale New Haven Hospital Interventional Psychiatry Service · Yale School of Medicine
Gerard Sanacora is George D. and Esther S. Gross Professor of Psychiatry; Director, Yale Depression Research Program; Co-Director, Yale New Haven Hospital Interventional Psychiatry Service at Yale School of Medicine. OpenAlex indexes 297 publications with 35,291 citations (h-index 87); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Psychiatry profiles in the findmyKOL directory.
Data verified 16 Oct 2026
Overview
Updated 18 Oct 2026
Gerard Sanacora, M.D., PH.D., is George D. and Esther S. Gross Professor of Psychiatry at Yale School of Medicine, Department of Psychiatry. The public record shows 297 publications with 35,291 citations (h-index 87), centered on Treatment of Major Depression, Electroconvulsive Therapy Studies, Neuroscience and Neuropharmacology Research. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 15 companies, 8 NIH-funded awards (1999–2014).
- Most recent indexed publication: 2026 · Neuropsychopharmacology
- Top research focus: Treatment of Major Depression
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 18 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 183.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Sponsor: Yale University
- Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
Sponsor: Yale University
- AZD6765 Severe Major Depressive Disorder (MDD) IV
Sponsor: AstraZeneca
Industry payments
Updated 18 Oct 2026
15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202512 payments
- Supernus Pharmaceuticals, Inc.Program year20251 payment
- Eli Lilly and CompanyProgram year20252 payments
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Benzodiazepine33.3%Clonazepam100%Part D<11 patientsNonergot Dopamine Agonist33.3%Pramipexole Dihydrochloride100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
8 NIH research awards on record, funded 1999–2014 per NIH RePORTER. The latest:
- Ex Vivo Assay for In Situ Brain-Wide Mapping of Glutamate/GABA Metabolism
Yale University
FY2014$515,895R01MH095104 - Ex Vivo Assay for In Situ Brain-Wide Mapping of Glutamate/GABA Metabolism
Yale University
FY2013$495,802R01MH095104 - Effects of Stress and Glutamatergic Agents on Glutamate Cycling and Behavior
Yale University
FY2013$351,691R01MH081211
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The Randomization Effect in a Double-Blind Placebo-Controlled Depression Study.
Journal of clinical psychopharmacology
Article2026 - Using connectome-based predictive models to reveal the systems standardized tests and clinical symptoms are reflecting.
Nature communications
Article2026 - Lower synaptic density in mood circuitry underlies depression in Parkinson's disease.
Brain communications
Article2026
Most-cited works
by citation count (OpenAlex)- 01Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressantsArticle1,779 citations2016
- 02The stressed synapse: the impact of stress and glucocorticoids on glutamate transmissionReview1,427 citations2011
- 03
- 04
- 05Towards a glutamate hypothesis of depressionArticle1,047 citations2011
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/gerard-sanacora-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
yalepodcasts.blubrry.net/2021/12/22/depression-ketamine-navigating-the-mental-health-care-with-gerard-sanacora-ashley-clayton
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalepodcasts.blubrry.net ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Editorial & leadership roles
journal and society appointments- Session chair
ACNP 2023 Annual Meeting: Larger Scale Data Informing the Use of ECT and Ketamine/Esketamine in Severe and Treatment Resistant Major Depressive Disorder
2023provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →psychiatrictimes.com ↗ - Fellow
American College of Neuropsychopharmacology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.yale.edu ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.yale.edu ↗
- Joel Elkes Research Award for Outstanding Contributions to Psychopharmacology
American College of Neuropsychopharmacology
2011provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.yale.edu ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.yale.edu ↗
Secondary affiliations
appointments beyond the home institution- Yale New Haven Hospital
Interventional Psychiatry Service (Co-Director)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Clinical Neuroscience Research Unit
Connecticut Mental Health Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →yalemedicine.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Harlan Krumholz, MD
Yale School of Medicine
Eric Winer, MD
Yale School of Medicine
Roy Herbst, MD, PhD
Yale School of Medicine
Robert Rosenheck, MD
Yale School of Medicine
Charles Nemeroff, MD
Dell Medical School
Maurizio Fava, MD
Massachusetts General Hospital
John Krystal, MD
Yale University
Jeffrey Lieberman, MD
Columbia University College of Physicians and Surgeons